ArticleInternational journal of clinical practice2021
New chalcone derivatives as effective against SARS-CoV-2 agent.
Article in International journal of clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Chalcones as Multi-target Ligands for Alzheimer's Disease: A Review of Synthetic Strategies and Therapeutic Promise.Mini reviews in medicinal chemistry · 2026Review
- Synthesis and Bioevaluation of Chalcones as Broad-Spectrum Antiviral Compounds Against Single-Stranded RNA Viruses.Biomolecules · 2025Article
- Design, synthesis, andRSC advances · 2025Article
- Synergistic activity between conventional antifungals and chalcone-derived compound against dermatophyte fungi and Candida spp.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- New O-alkyl Chalcone Derivative Exhibits Antiproliferative Potential in Colorectal and Cervical Cancer Cells by Inducing G0/G1 Cell Cycle Arrest and Mitochondrial-mediated Apoptosis.Current medicinal chemistry · 2025Article
- Organohalogen chalcones: design, synthesis, ADMET prediction, molecular dynamics study and inhibition effect on acetylcholinesterase and carbonic anhydrase.Molecular diversity · 2024Article
- Structure-Activity Relationship of Natural Dihydrochalcones and Chalcones, and Their Respective Oxyalkylated Derivatives as Anti-Plants (Basel, Switzerland) · 2024Article
- Antiviral and antimicrobial applications of chalcones and their derivatives: From nature to greener synthesis.Heliyon · 2023Review
- Studies on the Nonalkaloidal Secondary Metabolites ofACS omega · 2023Article
- Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro.Frontiers in pharmacology · 2023Article
- Recruitment of chalcone's potential in drug discovery of anti-SARS-CoV-2 agents.Phytotherapy research : PTR · 2022Review
- Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus.Plants (Basel, Switzerland) · 2022Review
- The green chemistry of chalcones: Valuable sources of privileged core structures for drug discovery.Frontiers in chemistry · 2022Review
- Progress of isolation, chemical synthesis and biological activities of natural chalcones bearing 2-hydroxy-3-methyl-3-butenyl group.Frontiers in chemistry · 2022Review
- New chalcone derivatives as effective against SARS-CoV-2 agent.International journal of clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFlavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs.
methodsDetermination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (C
resultsAntiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates.
conclusionsComputational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from -4.370 to -2.748 kcal/mol along with their toxicological, ADME, and drug-like properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.